AltruBioLogo.png
AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
January 23, 2023 09:00 ET | AltruBio Inc.
SAN FRANCISCO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBioLogo.png
AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023
January 19, 2023 11:00 ET | AltruBio Inc.
SAN FRANCISCO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBioLogo.png
AltruBio to Present at Biotech Showcase™ 2023
January 05, 2023 08:00 ET | AltruBio Inc.
SAN FRANCISCO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBioLogo.png
AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
December 10, 2022 10:00 ET | AltruBio Inc.
-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured by best response- -Participants with TR-aGVHD (11 of 12 concomitant ruxolitinib) achieved an ORR of 67% and CR...
AltruBioLogo.png
AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases
December 08, 2022 08:00 ET | AltruBio Inc.
The Company will Provide an Overview of its Immune Checkpoint Enhancer (ICE) Platform Clinical Proof-of-Concept Data from its First Generation ICE, ALTB-168, will be Presented, Including Development...
AltruBioLogo.png
AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis
December 06, 2022 08:00 ET | AltruBio Inc.
-Next-generation PSGL-1 agonist antibody with clinically proven mechanism of action receives IND clearance- -Phase 1 clinical trial expected to launch in 1H 2023 and will evaluate the safety,...
AltruBioLogo.png
AltruBio to Present at Stifel 2022 Healthcare Conference
November 08, 2022 08:00 ET | AltruBio Inc.
SAN FRANCISCO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBioLogo.png
AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
November 03, 2022 09:00 ET | AltruBio Inc.
SAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBioLogo.png
AltruBio President and CEO Judy Chou Appointed to the Governing Board of California’s Stem Cell & Gene Therapy Agency
November 01, 2022 08:00 ET | AltruBio Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBioLogo.png
AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference
September 16, 2022 13:53 ET | AltruBio Inc.
SAN FRANCISCO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...